Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9287MR)

This product GTTS-WQ9287MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ9287MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2030MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ792MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ9744MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JR-141
GTTS-WQ7115MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FE 999302
GTTS-WQ9415MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ4190MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ6473MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P-59
GTTS-WQ4645MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986036
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW